← Back to Search

Social Media Strategy for COVID-19 Vaccination Equity

N/A

Waitlist Available

Led By Damon Centola, PhD

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged 18 and above

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediate after intervention

Awards & highlights

Study Summary

This trial is using social media to try and bridge the digital divide in social technology between African American and Latinx populations and white and Asian members of online communities.

Who is the study for?

This trial is for adults over 18 living in the United States with internet access. It aims to improve health equity and COVID-19 vaccination rates among at-risk populations, particularly addressing challenges faced by African American and Latinx communities.Check my eligibility

What is being tested?

The study tests an online social network intervention designed to reduce digital divide and increase engagement with health-promoting information. Participants will be compared to a control group without this intervention.See study design

What are the potential side effects?

Since this trial involves an online social network intervention rather than a medical treatment, traditional physical side effects are not expected. However, participants may experience changes in their online interactions or exposure to information.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ immediate after intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~immediate after intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and immediate after intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

COVID-19 vaccination attitude

COVID-19 vaccination intention

COVID-19 vaccine safety perception

Secondary outcome measures

COVID-19 vaccine belief

Trial Design

6Treatment groups

Experimental Treatment

Group I: Independent Control of Homogeneous PopulationsExperimental Treatment1 Intervention

Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.

Group II: Independent Control of Diverse PopulationsExperimental Treatment1 Intervention

Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.

Group III: Egalitarian Networks of Homogeneous PopulationsExperimental Treatment1 Intervention

Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.

Group IV: Egalitarian Networks of Diverse PopulationsExperimental Treatment1 Intervention

Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.

Group V: Centralized Networks of Homogeneous PopulationsExperimental Treatment1 Intervention

Centralized networks have a small number of influential individuals, called "hubs," with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected "influencers." Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.

Group VI: Centralized Networks of Diverse PopulationsExperimental Treatment1 Intervention

Centralized networks have a small number of influential individuals, called "hubs," with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected "influencers." Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, DavisOTHER

909 Previous Clinical Trials

4,699,654 Total Patients Enrolled

University of California, San FranciscoOTHER

2,498 Previous Clinical Trials

11,931,872 Total Patients Enrolled

University of PennsylvaniaLead Sponsor

1,998 Previous Clinical Trials

42,874,905 Total Patients Enrolled

Media Library

Independent Control Clinical Trial Eligibility Overview. Trial Name: NCT04779827 — N/A

Heart Disease Research Study Groups: Egalitarian Networks of Diverse Populations, Centralized Networks of Diverse Populations, Independent Control of Diverse Populations, Egalitarian Networks of Homogeneous Populations, Centralized Networks of Homogeneous Populations, Independent Control of Homogeneous Populations

Heart Disease Clinical Trial 2023: Independent Control Highlights & Side Effects. Trial Name: NCT04779827 — N/A

Independent Control 2023 Treatment Timeline for Medical Study. Trial Name: NCT04779827 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots available in the ongoing clinical trial?

"Clinicaltrials.gov confirms that this medical investigation is on-going, with its initial posting being made on May 4th 2021 and the latest alterations to it occurring June 30th 2022."

Answered by AI

How many participants are actively engaging in this clinical trial?

"Yes, the information found on clinicaltrials.gov confirms that this medical study is actively enrolling participants. The trial was first posted on May 4th 2021 and has since been updated as of June 30th 2022. Currently, 1920 patients need to be recruited from 1 site."

Answered by AI

Recent research and studies

Proceedings of the National Academy of SciencesJournal

Social Learning and Partisan Bias in the Interpretation of Climate Trends

Guilbeault, Douglas, Joshua Becker, and Damon Centola. 2018. “Social Learning and Partisan Bias in the Interpretation of Climate Trends”. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1722664115.

Plos OneJournal

Networked Collective Intelligence Improves Dissemination of Scientific Information Regarding Smoking Risks

Guilbeault, Douglas, and Damon Centola. 2020. “Networked Collective Intelligence Improves Dissemination of Scientific Information Regarding Smoking Risks”. Edited by Fabiana Zollo. Plos One. Public Library of Science (PLoS). doi:10.1371/journal.pone.0227813.

clinicaltrials.govStudy

Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks

Damon Centola, PhD 2021. "Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04779827.

All > Coronavirus